- First Cohort: Healthy Male and female adults 60 to 64 years of age at time of
enrollment.
- Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of
enrollment.
- Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of
enrollment.
- Previous immunization with any licensed or experimental pneumococcal vaccine.
- Serious chronic disorders including metastatic malignancy, severe chronic obstructive
pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with
or without dialysis, clinically unstable cardiac disease, or any other disorder which
in the investigator's opinion precludes the subject from participating in the study.
- Known or suspected impairment of immunological function.